CA 125 Test Market Size & Share Analysis - Growth Trends and Forecast (2026 - 2031)

Global CA 125 Test Market Trends and Insights

Rising Ovarian Cancer Surveillance Demand

The 330,731 ovarian cancer cases recorded globally in 2024 provide a large base for ongoing clinical monitoring.^{[1]International Agency for Research on Cancer, “Global Cancer Observatory: Ovary Fact Sheet, GLOBOCAN 2024,” World Health Organization, gco.iarc.who.int} A 2026 projection estimated that annual global cases could reach 477,000 by 2050.^{[2]“Comprehensive Assessment of Incidence, Mortality, and Lifetime Risk of Ovarian Cancer: A Global Study With Forecasts to 2050,” Journal of Gynecologic Oncology, doi.org} In the United States, Medicare coverage recognizes CA 125 for specified ovarian and primary peritoneal carcinoma indications. The coverage framework supports repeat testing after therapy, which makes demand less dependent on a single clinical visit. The CA 125 testing market, therefore, relies on established care pathways as well as new diagnostic demand. Rising patient numbers could increase the number of patients who enter these follow-up pathways across high-income and emerging health systems.

Expansion of Automated Immunoassay Menus in Core Laboratories

Automated platforms allow laboratories to run CA 125 within wider tumor-marker menus from a single blood sample. Siemens Healthineers offers CA 125 testing on its Atellica platform, and Roche offers the Elecsys CA 125 II assay within its laboratory diagnostics portfolio.^{[3]Siemens Healthineers, “Atellica IM CA 125II Method Sheet, Revision 05,” Siemens Healthcare Diagnostics, doclib.siemens-healthineers.com}This model reduces the operational burden of adding a test once an analyzer has already been installed. It can also make CA 125 easier to order with other tumor markers when clinicians require a broader laboratory assessment. Japan’s health ministry sets reimbursement and laboratory diagnostics policies that shape the adoption environment for automated testing. The CA 125 testing market is supported when laboratories replace smaller systems with high-throughput analyzers that have established tumor-marker menus.

Bundling of CA 125 With HE4 and ROMA Workflows

CA 125 is increasingly used with HE4 in the Risk of Ovarian Malignancy Algorithm, or ROMA, for women with an adnexal mass. Abbott describes its ovarian cancer biomarker offering as incorporating CA 125, HE4, and ROMA. Medicare’s local coverage policy addresses multimarker serum tests related to ovarian cancer testing. The paired workflow increases the value of a system that can run both assays on the same platform. It also favors suppliers with a broad oncology menu during laboratory procurement. The CA 125 testing market gains volume when the marker is ordered as part of a defined clinical workflow rather than as an isolated test. Changes in clinical thresholds or guidelines could still affect how CA 125 is weighted within a multi-marker assessment.

AI-Enabled Reflex Testing and Result Triage

A 2025 study of 9,799 patients with adnexal masses found that a LightGBM model using CA 125, age, and ROMA achieved an AUC of 0.9675. The study reported that the model could predict ovarian cancer 17 days earlier than conventional pathological assessment. A separate 2026 multicenter study across 11 centers in 6 countries reported an AUC of 0.930 for a deep-learning system that included CA 125 as an optional predictor. These findings position the test as a useful data input for clinical decision support rather than only a standalone result. Laboratory information systems could use structured risk outputs to support reflex testing workflows where they are clinically and operationally appropriate. Such use could improve the practical value of results without changing the underlying assay.

Limited Test Specificity in Benign Gynecologic Conditions

CA 125 levels can be elevated in benign conditions, including endometriosis, fibroids, and pelvic inflammatory disease. This limits the test’s diagnostic specificity, particularly for premenopausal women. A 2025 external validation study examined CA 125 and age-based models in 342,278 women tested in English primary care. Age-adjusted thresholds improved specificity compared with a fixed 35 U/mL cutoff, but performance remained lower in women under 50. False-positive results can lead to additional imaging, specialist referrals, and sometimes laparoscopy. This may limit clinician confidence in standalone CA 125 testing for lower-risk patients and supports the move toward panel-based assessment.

Low Sensitivity for Early-Stage Ovarian Cancer Detection

CA 125 is elevated in only 50% of Stage I ovarian cancer cases, which limits its use as a standalone population-screening test. This limitation restricts the range of settings in which the assay can serve as the primary diagnostic tool. Newer diagnostic approaches are evaluating CA 125 with other biomarkers and clinical information. A 2026 study in endometriosis showed that combining CA 125 with CXCL12 and VEGF improved the diagnostic AUC from 0.6260 for CA 125 alone to 0.8823 for the combined panel. This evidence supports the marker’s role as one component of a broader diagnostic approach. It also places pressure on suppliers that only offer a single assay and do not support multi-marker workflows.

*Our forecasts treat driver/restraint impacts as directional, not additive. The impact forecasts reflect baseline growth, mix effects, and variable interactions.

Segment Analysis

By Product Type: Instruments Lead Revenue While Reagents Support Growth

Analyzers and instruments accounted for 52.42% of the CA 125 testing market size in 2025. This position reflects the cost of high-throughput and semi-automated immunoassay equipment used by laboratories. An installed analyzer can create ongoing demand for compatible reagents and consumables. That relationship gives established platform suppliers recurring revenue from their existing laboratory base. 

Reagents and kits are forecasted to grow at a 6.47% CAGR through 2031, the fastest rate among product categories. The growth outlook reflects the expansion of CA 125 menus on installed systems and more frequent testing within multi-marker pathways. European in vitro diagnostic rules also increase documentation demands for suppliers that seek to register relevant products in the region.

By Technology: Automated Systems Retain Scale While Semi-Automated Immunoassay Systems Expand

Automated immunoassay systems held 43.53% of the CA 125 testing market share in 2025. These systems are used in laboratories that process many analytes and require standardized workflows. CA 125 can be run with other tumor markers on the same platform, which supports routine laboratory use. 

Semi-automated immunoassay systems are forecasted to grow at a CAGR of 7.23% through 2031. Their expansion is driven by the increasing demand for cost-effective and rapid CA 125 testing in community hospitals, diagnostic centers, and decentralized laboratory settings. These systems offer a practical balance between automation and affordability, making them attractive for routine ovarian cancer monitoring and follow-up testing. Growth is particularly strong in emerging healthcare markets, although fully automated platforms remain the preferred choice in large reference laboratories due to their higher throughput and workflow efficiency.

By Indication: Cancer Remains the Core Use, While Endometriosis Gains Attention

Cancer accounted for 40.16% of the CA 125 testing market in 2025. CA 125 is established in the monitoring of epithelial ovarian carcinoma, and it is elevated in 80% of patients with that disease type. Its use in treatment follow-up provides a stable clinical base for testing. Uterine fibroids and liver disease provide smaller indication areas, but their clinical use is not as consistently defined by formal protocols. 

Endometriosis is forecasted to grow at a 6.72% CAGR through 2031. The growth outlook reflects interest in non-surgical diagnostic pathways and the use of CA 125 within multi-biomarker panels. In a 2026 prospective study of 188 patients in China, the CA 125, CXCL12, and VEGF panel reached an AUC of 0.8823, compared with 0.6260 for CA 125 alone. These activities support the use of CA 125 as part of a combined assessment rather than as a definitive test by itself.

By End-User: Hospitals Provide the Largest Base While Clinical Laboratories Gain Volume

Hospitals accounted for 42.34% of revenue in 2025. They remain important for baseline testing after surgery, monitoring during chemotherapy, and pelvic-mass workups that require CA 125 and HE4. Their laboratories also manage patients who need fast access to oncology teams and specialist services. This supports a reliable role for hospital-based testing even as work shifts to other settings. 

Clinical laboratories are forecasted to grow at a 7.63% CAGR through 2031. Oncology monitoring is moving toward outpatient and reference laboratory networks with high-throughput automation and bulk reagent purchasing. Diagnostic centers also support periodic monitoring outside active hospital treatment. Academic and research organizations have a smaller revenue role, but they remain important because many multi-marker and AI-enabled approaches begin in clinical research.

Geography Analysis

North America held 47.33% of the CA 125 testing market share in 2025. Medicare coverage and local policy for ovarian cancer-related multimarker tests create a structured basis for testing in the United States. This framework supports repeat testing after therapy and helps laboratories plan for consistent volumes. Canada contributes through provincial oncology programs, while private hospitals in Mexico add demand for immunoassay platforms. 

Europe was the second-largest regional market in 2025, with Germany and the United Kingdom holding the largest national shares. France, Italy, and Spain contribute through public hospital procurement and centralized laboratory contracts. The European Union’s in vitro diagnostic regulation raises technical documentation and conformity assessment requirements for relevant immunoassay platforms. This favors suppliers that can maintain compliant portfolios and support customers through regulatory changes. Asia-Pacific is forecasted to grow at an 8.24% CAGR through 2031, supported by China’s oncology patient base, South Korean automation investment, India’s diagnostic networks, and Japan’s reimbursement environment.

The Middle East, Africa, and South America remain earlier-stage regions for CA 125 testing. Their growth depends on laboratory infrastructure, procurement capacity, and access to automated immunoassay systems. Private hospitals in Saudi Arabia and the United Arab Emirates are expanding oncology-testing capabilities, while South Africa has established academic hospital networks using major platforms. Brazil leads South American revenue through its private diagnostic laboratories and public oncology programs, while quantitative lateral-flow kits offer an accessible option for laboratories without full automation.